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Methods: From a multicentric French registry (DAI-PP Registry, 2002-
2012), 5547 consecutive patients, with coronary artery disease or dilated car-
diomyopathy, were implanted with an ICD in the setting of primary preven-
tion. From 5338 (96%) patients with full information, we determined
prevalence, independent associated factors and prognosis of the occurrence of
early (within 30 days post implantation) complications. 
Results: Early complications occurred in 709 patients (13.5%), mainly
related to lead dysfunction or hematoma (56%). Independent associated fac-
tors to early complications were renal impairment (clearance <30ml/min,
OR=1.69, 95% CI 1.19-2.41, P<0.001), cardiac resynchronization therapy
(OR=1.61, 95% CI 1.17-2.21, P=0.004), anticoagulant therapy (OR=1.30,
95% CI 1.04-1.63, P=0.02) and older age (OR=1.02, 95% CI 1.01-1.02,
P=0.03). During a mean follow-up of 3.1±2.3 years, 834 patients experienced
≥1 complication (15.6%), mainly inappropriate therapies and/or lead dysfunc-
tion (75%). After consideration of potential confounding factors, early compli-
cations were significantly associated with the occurrence of late complications
(OR=2.15, 95% CI 1.73-2.66, P<0.0001) and a higher risk of overall mortality
(OR=1.48, 95% CI 1.17-1.88, P=0.001).
Conclusions: Early complication is a frequent event after ICD implantation
occurring in one out of six patients. These events are associated with a signif-
icant increase of late complications and overall mortality. 
0456
Therapeutic management in ambulatory elderly patients with atrial
fibrillation: the S.AGES cohort
Olivier Hanon (1), Jean-Sébastien Vidal (1), George Pisica (1), Linda
Benattar-Zibi (2), Philippe Bertin (3), Gilles Berrut (4), Emmanuelle
Corruble (5), Genevieve Derumeaux (6), Bruno Falissard (5), Francoise
Forette (7), Florence Pasquier (8), Michel Pinget (9), Rissane Ourabah (10),
Laurent Becquemont (11), Nicolas Danchin (12)
(1) Hôpital Broca, Gérontologie 1, Paris, France – (2) Orpea, Puteaux ,
France – (3) CHU Limoges, Rhumatologie, Limoges, France – (4) CHRU
Nantes, Gériatrie, Nantes, France – (5) INSERM U669, Le Kremlin-
Bicêtre, France – (6) CHU Lyon, Cardiologie, Lyon, France – (7) Fonda-
tion Nationale de la Gérontologie, Paris, France – (8) CHU Lille, Neuro-
logie, Lille, France – (9) CHU Strasbourg, Endocrinologie et maladies de
la nutrition, Strasbourg, France – (10) Faculté de Médecine Paris-Sud, Le
Kremlin-Bicêtre, France – (11) CHU Hôpital Bicêtre-APHP, Néphrologie,
Le Kremlin-Bicêtre, France – (12) CHU Hôpital Européen Georges Pom-
pidou (HEGP) – APHP, Cardiologie, Paris, France
Few data on therapeutic management of patients over 80 years with non-
valvular atrial fibrillation (AF) are available in general population. 
Objectives: The objectives of the AF-S.AGES cohort (Sujets AGÉS) were
to describe real-life therapeutic management of non-institutionalized elderly
subjects with AF according to age groups, i.e., 65-79 and ≥80 years and to
determine factors associated with anticoagulant treatment.
Methods: General practitioners recruited 1072 patients aged ≥65 years old
between 2009 and 2011. General characteristics were first evaluated in the
overall sample and according to age groups and use of anticoagulant treatment
at inclusion. 
Results: Mean age was 78.0 (SD 6.5) years and 42% were older than
80 years. In the overall sample, 19% of patients had paroxysmal AF, 15% per-
sistent, 56% permanent and for 10% AF type was unknown. Vitamin K anta-
gonists (VKA) were used in 77% of patients, antiplatelet therapy in 17% and
12% of patients did not receive any antithrombotic treatment. There were no
differences between age-groups (< 80 or ≥80 years) for VKA (78 vs. 76%,
p=0.58). Rate control drugs were more frequently used (55%) than rhythm
control drugs (37%). Class I and class II antiarrhythmic drugs were less often
used in octogenarians than in younger patients (5.6% vs. 12.3%, p<0.001 and
36 vs. 41%, p<0.05). Among patients ≥80 years old, VKA use was associated
with permanent AF younger age and cancer. Among patients < 80 years old,
the use of VKA was associated with permanent AF and preserved functional
autonomy. HAS-BLED and HEMORR2HAGES scores were associated with
non-use of VKA in subjects ≥80 and < 80 years, CHADS2 and CHA2DS2-
VASc scores were not associated with VKA use in both groups.
Conclusions: We observed a higher use of anticoagulant therapy in elderly
AF outpatients even after 80 years when compared with previous studies.
These results suggest that recent international guidelines are better imple-
mented in the elderly population. 
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Purpose of the study: to evaluate the role of the mechanism of paroxysmal
supraventricular tachycardia (SVT) on the incidence of spontaneous atrial
fibrillation (AF). The relation between SVT and AF is well-known but its fre-
quency could depend on the mechanism of SVT.
Methods: 1559 patients, mean age 49±19 years, with SVT and without
anterograde conduction over an accessory pathway (AP) were referred for
electrophysiological study (EPS), performed in control state and after isopro-
terenol. 
Results: SVT was related to atrioventricular nodal re-entrant tachycardia
(AVNRT) in 1262 patients (group I), either typical (n=1180)(group IA) or
atypical (n=183)(group IB). In 297 patients SVT was related to atrioventric-
ular re-entrant tachycardia (AVRT) due to a concealed AP (group II). At the
initial evaluation 47 group I patients (4%)(44 of group IA, 4%, 3 of group IB,
2%), 6 of group II (2%) had presented at least one episode of sustained AF
(NS). During follow-up (mean 3±2 years), 97 patients developed AF, 86 of
group I (7%)(71 of group IA, 6%, 15 of group IB, 8%),11 of group II (4%).
AF risk was higher in group I than in group II (p<0.045); differences remain
significant for group IA/IB. When patients with AF at first study were
excluded AF risk was similar in all groups: 5% of group I)(4% of group IA;
6.5% of group IB)(0.06) and 3% of group II. Ablation of slow pathway/AP
was performed in 1099 patients, 67% of group I (69% of group IA, 51% of
group IB), 64% of group II (NS). AF risk was paradoxically higher in patients
in whom ablation was performed in group I (6.7% in group I, 7% in group IA,
13% in group IB), compared to patients without ablation (4% in group I, 4%
in group IA, 3% in group IB)(p<0.022) and was unchanged in group II (4%
after ablation and 3% in patients without ablation).
Conclusions: AF-related SVT was rare (3%), independent on the mecha-
nism of SVT. The risk of subsequent AF after a follow-up of 3 years increased
to 6% and was near 5% in patients without AF at initial evaluation; it was
only higher in patients with atypical AVNRT than in patients with AVRT. The
risk was not affected by the ablation of the slow pathway or the AP. 
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Thromboprophylaxis for patients with coronary artery disease and atrial
fibrillation (AF) is an issue when patients undergo intracoronary stent place-
ment and several recent guidelines propose slightly different management. 
Methods: All patients with AF and stent implantation seen between 2000
and 2010 in 3 academic hospitals were identified in a database and followed
up for mortality, stroke and bleeding events.
Results: Among all patients seen between 2000-2010, 343 had AF, coro-
nary stent placement and CHADS2 score=0 or 1. In these patients, OAC was
